Research programme: anti-Bradykinin receptor B1 antibodies - Immune Biosolutions
Alternative Names: B1R antibodiesLatest Information Update: 28 Feb 2023
At a glance
- Originator Immune Biosolutions
- Class Antibodies; Antineoplastics
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Colorectal cancer; Lung cancer; Prostate cancer; Triple negative breast cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Colorectal-cancer in Canada (Parenteral)
- 28 Feb 2023 No recent reports of development identified for research development in Lung-cancer in Canada (Parenteral)
- 28 Feb 2023 No recent reports of development identified for research development in Prostate-cancer in Canada (Parenteral)